SFCA3007: Significantly Greater Improvements in Post-Dose FEV1 Seen with FSC250/50 vs. FP250

? FEV1 (ml)

Endpoint

(14%)

(27%)

*Pɘ.001 vs FP

*

Previous slide

Next slide

Back to first slide

View graphic version